Literature DB >> 17643658

Lithium-induced nephrogenic diabetes insipidus after coronary artery bypass.

Matthew F Leeman1, Alain Vuylsteke, Andrew J Ritchie.   

Abstract

We present a case of nephrogenic diabetes insipidus that occurred after on-pump coronary artery bypass grafting in a patient taking long-term lithium carbonate. Lithium toxicity (2.79 mmol/L) was identified on postoperative day 9. Serum sodium peaked at 175 mmol/L on postoperative day 21. Serum osmolality peaked at 384 mOsm/kg H2O, with a urinary osmolality of 403 mOsm/kg H2O. The patient was ultimately managed with hemofiltration and high-dose 1-desamino-8-D-arginine-vasopressin. Recommendations are made based on our experience of this case. In patients on long-term lithium therapy, the potentially life-threatening complication of lithium-induced nephrogenic diabetes insipidus should be specifically anticipated and managed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17643658     DOI: 10.1016/j.athoracsur.2007.03.005

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  3 in total

1.  Temporary diabetes insipidus in 2 men after on-pump coronary artery bypass grafting.

Authors:  Ihsan Sami Uyar; Veysel Sahin; Besir Akpinar; Volkan Yurtman; Feyzi Abacilar; Faik Fevzi Okur; Mehmet Ates
Journal:  Tex Heart Inst J       Date:  2013

2.  Signalling through the type 1 insulin-like growth factor receptor (IGF1R) interacts with canonical Wnt signalling to promote neural proliferation in developing brain.

Authors:  Qichen Hu; Seong Yong Lee; John R O'Kusky; Ping Ye
Journal:  ASN Neuro       Date:  2012-07-10       Impact factor: 4.146

3.  Secondary oxalosis induced by xylitol concurrent with lithium-induced nephrogenic diabetes insipidus: a case report.

Authors:  Shinobu Takayasu; Aya Kamba; Kazutaka Yoshida; Ken Terui; Yutaka Watanuki; Noriko Ishigame; Satoru Mizushiri; Tetsu Tomita; Kazuhiko Nakamura; Norio Yasui-Furukori; Makoto Daimon
Journal:  BMC Nephrol       Date:  2020-05-01       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.